Company intelligence / Profile preview

Shandong Mingren Freda Pharmaceutical

Jinan, Shandong, Chinaen.fredabiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Shandong Mingren Freda Pharmaceutical is engaged mostly in generics and APIs, notably performing bioequivalence studies for drugs such as tofacitinib citrate (JAK inhibitor, generic of Pfizer’s Xeljanz). Additional published work includes early pharmacology and drug delivery research. No novel clinical efficacy data for novel therapeutics identified; the company is primarily focused on manufacturing, development, and regulatory equivalence research for established drugs.[9]

Therapeutic areas: OtherImmunologyRheumatology
Modalities: Small moleculeBiologic conjugate
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Shandong Mingren Freda Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shandong Mingren Freda Pharmaceutical.

Explore the full profile